Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents

Urology

Volumn 57, Issue 4, 2001, Pages 56-63

  Nelson, William G ^a   Wilding, George ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ALITRETINOIN; ANTIANDROGEN; ARZOXIFENE; ATRASENTAN; BEXAROTENE; BICALUTAMIDE; CELECOXIB; EFLORNITHINE; FINASTERIDE; LONAFARNIB; SEX HORMONE; SULINDAC SULFONE; TIPIFARNIB; UNCLASSIFIED DRUG; ZILEUTON;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER RESEARCH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; HIGH RISK POPULATION; HUMAN; MINORITY GROUP; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CELL DIFFERENTIATION; CELL DIVISION; DRUG EVALUATION; ESTROGEN RECEPTOR MODULATORS; FINASTERIDE; GENE THERAPY; GROWTH SUBSTANCES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 0034974881     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00942-0     Document Type: Article

References (59)

1. Epidemiologic evidence regarding predisposing factors to prostate cancer
2. Cancer incidence in five continents. Volume VII
3. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County
4. Case-control study of diet and prostate cancer in China
5. Diet and prostatic cancer: A case-control study in Hawaii
6. A prospective study of dietary fat and risk of prostate cancer
7. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases
8. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer
9. Tomatoes, tomato-based products, lycopene, and cancer: Review of the epidemiologic literature
10. Phytoestrogen intake and prostate cancer: A case-control study using a new database
11. Molecular genetics of prostate cancer
12. Molecular advances in prostate cancer
13. The human genome project and the future of medicine
14. Cancer genome anatomy project set for take-off
15. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial
16. Treatment with finasteride following radical prostatectomy for prostate cancer
17. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer
18. Design of the Prostate Cancer Prevention Trial (PCPT)
19. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression
20. Fenretinide: Induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells
21. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid
22. N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells
23. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells
24. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1
25. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
26. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion
27. The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3)
28. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin
29. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo
30. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
31. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
32. p21ras is modified by a farnesyl isoprenoid
33. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides
34. Carboxyl methylation and farnesylation of transducin gamma-subunit synergistically enhance its coupling with metarhodopsin II
35. In vivo farnesylation of rat rhodopsin kinase
36. In vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits
37. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
38. Genistein, a specific inhibitor of tyrosine-specific protein kinases
39. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
40. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
41. 2 in human prostatic carcinoma cells
42. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells
43. Arachidonic acid stimulates prostate cancer cell growth: Critical role of 5-lipoxygenase
44. 5,8,11,14-Eicosatetraynoic acid inhibits PC3 DNA synthesis and cellular proliferation, in part due to its 5′-lipoxygenase activity
45. Prostate cancer vaccines: Current status
46. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer
47. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate
48. Marimastat (BB2516): Current status of development
49. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice
50. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma
51. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
52. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease
53. Prevention of carcinogenesis by protease inhibitors
54. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer
55. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial
56. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells
57. Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells
58. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia
59. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis